Related Experiment Video

Updated: Jul 10, 2026

Transradial Access Chemoembolization for Hepatocellular Carcinoma Patients
05:31

Transradial Access Chemoembolization for Hepatocellular Carcinoma Patients

Published on: September 20, 2020

Sorafenib TARGET trial results in Spanish patients

J Bellmunt1, J L González-Larriba, M A Climent

  • 1Servicio de Oncología. Hospital General Universitari Vall d'Hebrón. Barcelona, Spain. jbellmunt@imas.imim.es

Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico
|November 3, 2007
PubMed
Abstract

Insights

Sorafenib treatment showed a trend towards improved progression-free survival in advanced clear-cell renal-cell carcinoma patients. Toxicity was manageable, aligning with broader international trial findings.

Area of Science:

  • Oncology
  • Clinical Trials
  • Pharmacology

Background:

  • Sorafenib demonstrated improved progression-free survival in advanced clear-cell renal-cell carcinoma (ccRCC) in the international TARGET trial.
  • This study focuses on a subpopulation of Spanish patients from the same trial.

Purpose of the Study:

  • To analyze the efficacy and safety of sorafenib in Spanish patients with advanced ccRCC.
  • To compare outcomes in Spanish patients with the overall results of the TARGET trial.

Main Methods:

  • Retrospective review of patient records from the TARGET trial database.
  • Collection of data on progression-free survival, overall survival, and toxicity.

Main Results:

  • Fifteen Spanish patients were included: 7 in the sorafenib arm and 8 in the placebo arm.
  • A trend towards improved progression-free survival was observed in the sorafenib group.
  • Sorafenib-related toxicity was manageable.

Conclusions:

  • The efficacy and toxicity findings in this Spanish subpopulation are consistent with the overall international TARGET trial results.
  • Sorafenib represents a viable treatment option for advanced ccRCC patients progressing after first-line therapy.

Related Concept Videos

Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Clinical Trials01:16

Clinical Trials

Clinical trials are prospective experimental studies conducted on humans to determine the safety and efficacy of treatments, drugs, diet methods, and medical devices. Using statistics in clinical trials enables researchers to derive reasonable and accurate conclusions from the collected data, allowing them to make wise decisions in uncertain situations. In medical research, statistical methods are crucial for preventing errors and bias.
There are four phases in a clinical trial. A phase one...